AbbVie has struck a deal with Samsung Bioepis and Biogen that will allow the partners to sell Imraldi—a biosimilar referencing Humira (adalimumab)—in Europe beginning in 2018, and, in exchange, they have agreed to drop a lawsuit challenging Humira’s patent, the companies announced April 5.
Humira is indicated in Europe for chronic non-infectious anterior uveitis.
Under terms of the agreement, AbbVie said it will grant patent licenses for the use and sale of Imraldi in Europe on a country-by-country basis, and the license period will begin in most European Union countries Oct. 16, 2018.
Samsung Bioepis and Biogen will make royalty payments to AbbVie, the companies said.
AbbVie also disclosed the deal will allow Samsung Bioepis to sell its biosimilar in the US beginning June 30, 2023.
The precise terms of the agreements are confidential, the companies said.
In 2017, AbbVie struck a deal with Amgen allowing it to sell its Humira biosimilar in the US beginning in January 2023 in exchange for royalty payments to AbbVie and dropping a patent challenge to Humira.